FDA Grants RMAT Status to UniQure’s AMT-130 Gene Therapy for Huntington’s Disease
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted